Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $107.65B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 ·
Decision snapshot: GSK stock price vs REXR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at REXR's multiple
Needs REXR P/E.
Implied fair value · at GSK's multiple
Needs GSK P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GSK FY 2025 (ended Dec 31, 2025) · REXR FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 71% equity / 29% debt · EV / Revenue 3.71x · EV / EBITDA 19.25x
Capital structure 72% equity / 28% debt · EV / Revenue 11.25x · EV / EBITDA 36.17x
GSK carries the larger enterprise value at $163.76B against $11.29B; GSK trades on the lower EV / Revenue multiple (3.71x vs 11.25x); GSK on the lower EV / EBITDA (19.25x vs 36.17x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GSK plc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Rexford Industrial Realty, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
—
0.38x
Net debt / EBITDA
Leverage against operating earnings
6.59x
9.89x
Cash and equivalents
Liquid reserves on the balance sheet
$3.40B
$165.78M
Total debt
Interest-bearing obligations outstanding
$44.87B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
GSK vs PFE
ELI LILLY & Co
GSK vs LLY
BRISTOL MYERS SQUIBB CO
GSK vs BMY
JOHNSON & JOHNSON
GSK vs JNJ
AbbVie Inc.
GSK vs ABBV
AMGEN INC
GSK vs AMGN
Prologis, Inc.
GSK vs PLD
EASTGROUP PROPERTIES INC
GSK vs EGP
SIMON PROPERTY GROUP INC /DE/
GSK vs SPG
Terreno Realty Corp
GSK vs TRNO
$3.25B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
